2038 A Phase I/II Study of Oral Pazopanib, a Receptor Tyrosine Kinase Inhibitor, in Neovascular Age Related Macular Degeneration

SciVee ◽

10.4016/40519.01 ◽

2012 ◽

Author(s):

Jason Slakter

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Macular Degeneration ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Age Related Macular Degeneration ◽

Receptor Tyrosine Kinase Inhibitor ◽

Download Full-text

P-359 Results from a phase I study of the oral VEGF receptor tyrosine kinase inhibitor ZD6474, in patients with solid tumors

Lung Cancer ◽

10.1016/s0169-5002(03)92327-0 ◽

2003 ◽

Vol 41 ◽

pp. S182

Author(s):

Catherine Wheeler ◽

Hironobu Minami ◽

Hiromichi Ebi ◽

Makoto Tahara ◽

Yasutsuna Sasaki ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Phase I Study ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.2530 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 2530-2530 ◽

Author(s):

P. Witteveen ◽

M. Langenberg ◽

H. M. Verheul ◽

J. Roodhart ◽

M. Roelvink ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Advanced Solid Tumors ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

Anti-Cancer Drugs ◽

10.1097/00001813-200603000-00015 ◽

2006 ◽

Vol 17 (3) ◽

pp. 353-358 ◽

Author(s):

Carlo L. Bello ◽

Laurie Sherman ◽

Jihao Zhou ◽

Lev Verkh ◽

John Smeraglia ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Receptor Tyrosine Kinase ◽

Healthy Subjects ◽

Phase I Study ◽

Kinase Inhibitor ◽

Sunitinib Malate ◽

Receptor Tyrosine Kinase Inhibitor ◽

Download Full-text

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-07-1466 ◽

2008 ◽

Vol 14 (7) ◽

pp. 2075-2081 ◽

Author(s):

Debashis Sarker ◽

Rhoda Molife ◽

T.R. Jeffrey Evans ◽

Maryon Hardie ◽

Cheryl Marriott ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Receptor Tyrosine Kinase Inhibitor ◽

Pharmacodynamic Study

Download Full-text

Corrections to “Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors”

Annals of Oncology ◽

10.1093/annonc/mdy532 ◽

2019 ◽

Vol 30 (6) ◽

pp. 1020 ◽

Author(s):

J.-C. Soria ◽

J. Cortes ◽

C. Massard ◽

J.-P. Armand ◽

D. De Andreis ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Advanced Solid Tumors ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

Annals of Oncology ◽

10.1093/annonc/mdq767 ◽

2011 ◽

Vol 22 (11) ◽

pp. 2508-2515 ◽

Author(s):

M.H.G. Langenberg ◽

P.O. Witteveen ◽

J. Roodhart ◽

M.P. Lolkema ◽

H.M.W. Verheul ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Advanced Solid Tumors ◽

Receptor Tyrosine Kinase Inhibitor

Download Full-text

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-08-1978 ◽

2009 ◽

Vol 15 (7) ◽

pp. 2552-2558 ◽

Author(s):

Kwok-K. Wong ◽

Paula M. Fracasso ◽

Ronald M. Bukowski ◽

Thomas J. Lynch ◽

Pamela N. Munster ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Phase I Study ◽

Kinase Inhibitor ◽

Erbb Receptor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Erbb Receptor Tyrosine Kinase

Download Full-text

Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-010-1405-y ◽

2010 ◽

Vol 67 (5) ◽

pp. 1119-1128 ◽

Author(s):

Haruyasu Murakami ◽

Yutaka Ueda ◽

Tatsu Shimoyama ◽

Noboru Yamamoto ◽

Yasuhide Yamada ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Solid Tumors ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Biological Studies ◽

Multiple Receptor

Download Full-text

453 Population pharmacokinetics (PK) and exposure/response relationships of the receptor tyrosine kinase inhibitor E7080 in phase I studies

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)72160-1 ◽

2010 ◽

Vol 8 (7) ◽

pp. 143 ◽

Author(s):

A. Gupta ◽

B. Koetz ◽

W. Hanekom ◽

J.P. O'Brien ◽

J. Wanders ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Population Pharmacokinetics ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Phase I Studies ◽

Receptor Tyrosine Kinase Inhibitor ◽

Exposure Response

Download Full-text

Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3002 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3002-3002 ◽

Author(s):

J. Drevs ◽

M. Medinger ◽

K. Mross ◽

U. Zirrgiebel ◽

R. Strecker ◽

...

Keyword(s):

Tyrosine Kinase ◽

Phase I ◽

Tyrosine Kinase Inhibitor ◽

Clinical Evaluation ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Vegf Receptor ◽

Receptor Tyrosine Kinase Inhibitor ◽

Advanced Tumors

Download Full-text